VR Adviser’s Adicet Bio ACET Stock Holding History

VR Adviser’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,481	Closed	-$1.89M	–	27
2021 Q2	$1.89M	Sell	11,481 -51,019	-82%	-$10.4M	0.23%	28
2021 Q1	$13.1M	Buy	+62,500	New	+$14.3M	1.42%	19

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

VR Adviser's ACET Position: Q3 2021 in Review

VR Adviser sold out of Adicet Bio (ACET) in Q3 2021, closing a stake of 11,481 shares — an estimated $1.89M sold.

VR Adviser first reported a position in ACET in Q1 2021 and held it in 2 quarters. The position peaked at $13.1M in Q1 2021. 58 funds tracked by Wall St. Rank hold ACET as of Q3 2021.

VR Adviser reported no remaining Adicet Bio position as of Q3 2021 after selling out during the quarter.
VR Adviser sold 11,481 Adicet Bio shares in Q3 2021, an estimated $1.89M.
VR Adviser first reported a position in Adicet Bio in Q1 2021 and held it in 2 quarters.
VR Adviser's Adicet Bio position peaked at $13.1M in Q1 2021.
58 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2021.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.